By: S. Marchetta MD, C. Douin MD, T. Couvreur MD, J. Djekic MD, B. Bastens MD, G. Houbiers MD, B. Massart MD, R. Roufosse MD, L. Longrée , C. Focan MD, PhD
The authors report the case of a patient suffering from cardiac amyloidosis with hepatic involvement. A prolonged remission was obtained under chemoimmunotherapy with CyBorD association (cyclophosphamide, bortezomib, and dexamethasone) and daratumumab. A literature survey is performed and presented.
(BELG J HEMATOL 2024;15(7):281–5)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
